<DOC>
	<DOCNO>NCT00268463</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin , capecitabine , floxuridine , work different way stop growth tumor cell , either kill cell stop dividing . Hepatic arterial infusion use catheter carry tumor-killing substance , chemotherapy , directly liver . Giving chemotherapy different way may kill tumor cell . It yet know whether give oxaliplatin capecitabine together hepatic arterial infusion floxuridine effective give oxaliplatin capecitabine alone treat patient undergo surgery and/or ablation liver metastasis due colorectal cancer . PURPOSE : This randomized phase III trial study oxaliplatin , capecitabine , hepatic arterial infusion floxuridine see well work compare oxaliplatin capecitabine treat patient undergo surgery and/or ablation liver metastasis due colorectal cancer .</brief_summary>
	<brief_title>Oxaliplatin Capecitabine With Without Hepatic Arterial Infusion With Floxuridine Treating Patients Who Are Undergoing Surgery and/or Ablation Liver Metastases Due Colorectal Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - Compare progression-free interval ( PFI ) patient undergo surgical resection and/or ablation hepatic metastasis colorectal cancer treat adjuvant therapy comprise oxaliplatin capecitabine v without hepatic arterial infusion floxuridine . Secondary - Compare overall survival liver PFI two treatment group . - Assess toxicity treatment regimen . - Compare self-reported symptom two treatment group . - Compare quality life treatment regimen . Tertiary - Examine prognostic worth , term PFI , specific molecular marker hepatic metastasis . OUTLINE : This randomize study . Patients stratify accord intended surgical technique ( surgical resection alone vs cryoablation radiofrequency ablation [ RFA ] alone vs combination resection ablation ) prior adjuvant chemotherapy regimen ( chemotherapy v without oxaliplatin v chemotherapy ) . Patients randomize 1 2 treatment arm . All patient undergo surgical resection and/or hepatic cryoablation RFA remove maximum 6 colorectal hepatic metastasis . Patients randomize arm II also undergo intra-arterial catheter applicable , pump placement . - Arm 1 ( oxaliplatin capecitabine ) : Within 4-6 week surgery and/or ablation , patient receive oxaliplatin IV 2 hour day 1 oral capecitabine twice daily day 1-14 . Treatment repeat every 21 day 8 course absence disease progression unacceptable toxicity . - Arm 2 ( oxaliplatin , capecitabine , hepatic arterial infusion floxuridine ) : Within 4-6 week surgery and/or ablation , patient receive continuous hepatic arterial infusion floxuridine day 1-14 , oxaliplatin IV 2 hour day 22 , oral capecitabine twice daily day 22-35 . Treatment repeat every 42 day 4 course absence unacceptable toxicity . Beginning course 5 , patient receive oxaliplatin IV 2 hour day 1 oral capecitabine twice daily day 1-14 . Treatment oxaliplatin capecitabine repeat every 21 day 4 course absence disease progression unacceptable toxicity . Quality life assess baseline , 4-6 week surgery ablation , approximately 18 week begin chemotherapy , 4-6 week begin last cycle chemotherapy . After completion study treatment , patient follow periodically . PROJECTED ACCRUAL : A total 400 patient accrue study .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Floxuridine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically* cytologically confirm colorectal adenocarcinoma No cellular type ( e.g. , sarcoma , lymphoma , carcinoid ) NOTE : *If primary colorectal tumor hepatic lesion identify time possible biopsy colorectal lesion , patient eligible without histologic confirmation colorectal primary cancer long radiographic study scan document characteristic colorectal cancer Synchronous metachronous metastatic disease confine liver No 6 hepatic metastatic lesion potentially resect ablate For patient present synchronous lesion ( ) colon and/or rectum , primary tumor must , opinion investigator , appear completely resectable Must able undergo surgery and/or ablation within 28 day follow randomization No evidence extrahepatic metastases No prior colorectal metastases No recurrent colorectal cancer concurrent hepatic metastasis PATIENT CHARACTERISTICS : Life expectancy ≥ 5 year , exclude colorectal cancer Eastern Cooperative Oncology Group ( ECOG ) ( Zubrod ) performance status 01 No malignancy within past 5 year except carcinoma situ cervix , melanoma situ , basal cell squamous cell skin cancer , carcinoma colon rectum Absolute granulocyte count ≥ 1,200/mm^3 Platelet count ≥ 100,000/mm^3 PT/international normalize ratio ( INR ) ≤ 1.5 unless patient therapeutic dos anticoagulant medication Total bilirubin ≤ upper limit normal ( ULN ) Alkaline phosphatase ≤ 2.5 ULN aspartate aminotransferase ( AST ) ≤ 2.5 time ULN Calculated creatinine clearance &gt; 50 mL/min Not pregnant lactate Negative pregnancy test Patients child bear potential must agree use adequate contraception Able swallow oral medication No preexisting chronic hepatic disease ( e.g. , chronic active hepatitis cirrhosis ) No grade 3 4 anorexia nausea No vomiting ≥ grade 2 No clinically significant peripheral neuropathy define ≥ grade 2 neurosensory neuromotor toxicity No psychiatric addictive disorder condition , opinion investigator , would preclude study participation PRIOR CONCURRENT THERAPY : Prior adjuvant fluorouracil alone combination levamisole , leucovorin calcium , irinotecan hydrochloride , oxaliplatin allow regimen complete &gt; 6 month ago No prior resection/ablation , hepatic arterial infusion therapy , systemic chemotherapy metastatic disease Prior excisional biopsy allow No prior radiotherapy liver No concurrent bevacizumab patient pump/catheter placement receive hepatic arterial infusion floxuridine Patients meet specific situation outline protocol pump placement may receive bevacizumab physician 's discretion No concurrent halogenated antiviral agent sorivudine brivudine patient receive fluorouracil , floxuridine , capecitabine No concurrent filgrastim ( GCSF ) , pegfilgrastim , sargramostim ( GMCSF ) primary prophylaxis neutropenia Following neutropenic event , drug may use physician 's discretion subsequent cycle No concurrent cancer therapy No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>liver metastasis</keyword>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>adenocarcinoma colon</keyword>
	<keyword>adenocarcinoma rectum</keyword>
</DOC>